Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 21045138)

1.

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT.

Clin Cancer Res. 2009 Nov 1;15(21):6639-48. doi: 10.1158/1078-0432.CCR-09-0951. Epub 2009 Oct 13.

2.

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

Corkery B, Crown J, Clynes M, O'Donovan N.

Ann Oncol. 2009 May;20(5):862-7. doi: 10.1093/annonc/mdn710. Epub 2009 Jan 15.

3.

EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.

Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H, Uchida K.

Oncol Rep. 2009 Feb;21(2):413-7.

PMID:
19148516
4.
5.

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT.

Mol Cancer Ther. 2008 Jul;7(7):1846-50. doi: 10.1158/1535-7163.MCT-08-0168.

6.

KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells.

Nakamura S, Okinaka K, Hirano I, Ono T, Sugimoto Y, Shigeno K, Fujisawa S, Shinjo K, Ohnishi K.

Leuk Res. 2008 Sep;32(9):1358-65. doi: 10.1016/j.leukres.2008.02.012. Epub 2008 Apr 2.

PMID:
18384876
7.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
8.

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C.

Cancer Res. 2008 Mar 1;68(5):1471-7. doi: 10.1158/0008-5472.CAN-07-5962.

9.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

10.

Heterogeneity of breast cancer and implications of adjuvant chemotherapy.

Razzak AR, Lin NU, Winer EP.

Breast Cancer. 2008;15(1):31-4. doi: 10.1007/s12282-007-0007-y.

PMID:
18224391
11.

FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression.

Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL.

J Biol Chem. 2008 Jan 4;283(1):453-60. Epub 2007 Nov 5.

12.

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.

Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT.

Mol Cancer Ther. 2007 Aug;6(8):2168-77. Epub 2007 Aug 1.

13.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

14.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

15.

Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO.

Histopathology. 2007 Mar;50(4):434-8.

PMID:
17448018
16.

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.

Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J.

Cell. 2007 Jan 26;128(2):281-94.

17.

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas.

Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR, Schmitt FC.

J Pathol. 2006 Aug;209(4):445-53.

PMID:
16739104
18.

A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression.

Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM.

Genes Dev. 2006 Jan 1;20(1):47-64.

19.

The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.

Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.

Cancer Res. 2005 Oct 15;65(20):9355-62.

20.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK.

Cancer Res. 2005 Aug 1;65(15):6910-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk